MERS-CoV

MERS-CoV
Name	MERS-CoV
Virus group	Betacoronavirus
Baltimore group	IV
Species	Middle East respiratory syndrome-related coronavirus
Genome	Positive-sense single-stranded RNA
Family	Coronaviridae
Subfamily	Orthocoronavirinae
Genus	Betacoronavirus
Year discovered	2012
Location discovered	Jeddah, Saudi Arabia

MERS-CoV Middle East respiratory syndrome coronavirus is a zoonotic betacoronavirus first identified in 2012 that causes Middle East respiratory syndrome, characterized by severe pneumonia and multi-organ failure in humans; it has prompted international investigation by clinical, veterinary, and public health institutions and remains a concern for hospital and zoonotic transmission. Major responses have involved collaborations among regional health ministries, the World Health Organization, research universities, and national disease centers during outbreaks in the Arabian Peninsula, South Korea, and elsewhere.

Virology

MERS-CoV is an enveloped, positive-sense RNA virus in the family Coronaviridae that encodes structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N), and accessory proteins that modulate host responses; genomic characterization and phylogenetic analyses have been performed by teams at King Abdullah University of Science and Technology, U.S. Centers for Disease Control and Prevention, Imperial College London, University of Oxford, University of Hong Kong, and the Institut Pasteur. Structural biology studies using cryo-electron microscopy by groups at Rockefeller University, Scripps Research Institute, Max Planck Society, and Harvard Medical School have resolved the S protein receptor-binding domain and its interaction with the dipeptidyl peptidase 4 receptor identified in work from University of Bonn and Mayo Clinic. Comparative genomics with Severe acute respiratory syndrome coronavirus sequences and analyses from National Institute of Allergy and Infectious Diseases researchers clarified recombination and mutation patterns; viral replication mechanisms share conserved features with other coronaviruses studied at Massachusetts Institute of Technology and Stanford University.

Transmission and Reservoirs

Zoonotic spillover investigations implicated dromedary camels as the primary animal reservoir based on seroepidemiology and viral isolates obtained in studies by teams at King Saud University, University of Cambridge, Zagazig University, and Qatar University; retrospective serosurveys in Kenya, Ethiopia, Egypt, and Oman expanded geographic understanding. Human-to-human transmission occurs mainly via close contact in households and healthcare settings documented in investigations by Seoul National University, University of Toronto, Public Health England, Singapore General Hospital, and Centers for Disease Control and Prevention (South Korea). Nosocomial amplification was prominent in outbreaks examined by National University Hospital (Singapore), Asan Medical Center, King Faisal Specialist Hospital, and Mayo Clinic Arizona, with studies on environmental stability by National Institutes of Health laboratories and aerosol research at Beth Israel Deaconess Medical Center.

Clinical Features and Diagnosis

Clinical presentation ranges from asymptomatic infection to severe pneumonia, acute respiratory distress syndrome, renal failure, and shock as described in case series from King Fahd Hospital of the University, Cleveland Clinic, Johns Hopkins Hospital, Sheikh Khalifa Medical City, and Royal Free Hospital. Comorbidities such as diabetes, chronic lung disease, and immunosuppression identified in cohorts at Ain Shams University, University College London Hospital, Mayo Clinic, and Cairo University increase risk of severe disease. Diagnostic confirmation relies on nucleic acid amplification tests targeting conserved regions of the genome developed by laboratories at World Health Organization (WHO), Centers for Disease Control and Prevention (USA), European Centre for Disease Prevention and Control, Korea Centers for Disease Control and Prevention, and commercial diagnostics companies; serologic assays and viral culture have been applied by University of Maryland School of Medicine and Charité – Universitätsmedizin Berlin.

Treatment and Prevention

There is no specific, universally approved antiviral therapy; clinical management centers on supportive care protocols refined at Royal Marsden Hospital, Cleveland Clinic, Toronto General Hospital, and King Khalid University Hospital. Experimental therapeutics and repurposed antivirals have been evaluated in preclinical and clinical studies at NIH Clinical Center, Erasmus Medical Center, University of Pennsylvania, University of California, San Francisco, and University of Tokyo, with monoclonal antibodies and interferon-based regimens investigated by industry partners such as Regeneron Pharmaceuticals, Gilead Sciences, and academic groups. Vaccine development efforts have involved platforms and trials led by teams at Moderna, Inovio Pharmaceuticals, GlaxoSmithKline, Takeda Pharmaceutical Company, University of Oxford, and National Institutes of Health, focusing on S protein immunogens, while infection prevention relies on personal protective equipment guidance from World Health Organization, isolation practices codified by Centers for Disease Control and Prevention (USA), and veterinary measures promoted by Food and Agriculture Organization and World Organisation for Animal Health.

Epidemiology and Outbreak History

Initial cases were reported in Jeddah and Riyadh regions of Saudi Arabia in 2012, followed by sporadic zoonotic cases and human clusters documented across the Middle East, with exported cases linked to travel to United Kingdom, Germany, France, Italy, Greece, and United Arab Emirates investigated by national public health agencies. A major hospital-centered outbreak in Gyeongsangbuk-do and Seoul in 2015 led to extensive contact tracing by Korea Centers for Disease Control and Prevention and international attention from WHO and World Bank analyses; seroepidemiologic work in Kenya, Somalia, and Bangladesh expanded reservoir mapping. National surveillance systems at Public Health England, Australian Department of Health, Singapore Ministry of Health, and Qatar Ministry of Public Health continue case detection and reporting recommended by International Health Regulations (2005).

Public Health Response and Control Measures

Responses have combined case identification, laboratory confirmation, contact tracing, hospital infection control, travel advisories, and animal surveillance coordinated among World Health Organization, United Nations, European Centre for Disease Prevention and Control, Centers for Disease Control and Prevention, and ministries of health in Saudi Arabia, Qatar, United Arab Emirates, Kuwait, Oman, Bahrain, and Jordan. Hospital preparedness measures informed by guidelines from Infectious Diseases Society of America, American Thoracic Society, Royal College of Physicians, and Saudi Ministry of Health emphasize airborne and droplet precautions, cohorting, and rapid diagnostic access. International research consortia and funding from institutions such as Wellcome Trust, Bill & Melinda Gates Foundation, National Science Foundation, and European Commission support cross-disciplinary work on surveillance, therapeutics, and vaccine development to limit future outbreaks.

Category:Coronaviruses